Sethi 2002.

Methods	Randomised control trial in India Head‐to‐head trial; 2 treatment groups gabapentin and lamotrigine Treatment period: 12 weeks No formal baseline period (however, all had ≥ 4 seizures, unclear over what time, despite treatment with maximum dose carbamazepine monotherapy)
Participants	52 children and adults Indian study Refractory focal seizures 48% male 27 gabapentin (19 male: 8 female), 25 lamotrigine (6 male: 19 female) Aged 10‐60 years
Interventions	Gabapentin: 300 mg day 1, 300 mg twice daily day 2, there after an increment of 300 mg daily until ≥ 50% reduction in seizures or toxic effects Lamotrigine: 50 mg/day for 2 weeks, increased to 50 mg twice daily, subsequently an increase of 50‐100 mg daily until above criteria met
Outcomes	Efficacy: seizure frequency, pattern of seizures, seizure‐free interval. Including % change of seizure frequency from baseline, responder rate (reduction in seizure frequency of ≥ 50%), response ratio Safety: biochemical investigations and adverse effects
Notes	As no clear baseline period, excluded from meta‐analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details provided
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	No details provided
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No participants seemed to be excluded from the results, but 1 participant in gabapentin group did not seem to be accounted for
Selective reporting (reporting bias)	Low risk	Included all prespecified expected outcomes
Other bias	Low risk	Study appeared free of other sources of bias